Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (27): 5111-5114.doi: 10.3969/j.issn.1673-8225.2010.27.040

Previous Articles     Next Articles

Haploidentical peripheral stem cell transplantation for treatment of hematologic malignancies in six cases

Wang Zhi-ming1, Wang Lin2, Chen Xiao-xia1, Luo Xian-sheng1, He Li-li1, Xu Dan-dan1, Li Xing1, Fu Rong-xiang1, Wang Yun-ying1, Li Li-qiong1, Huang Zi-ying1, Tan Lian1   

  1. 1 Department of Hematology, Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University, Haikou People’s Hospital, Haikou  570208, Hainan Province, China; 2 Department of Hematology and Oncology, Hainan Provincial Nong Ken Hospital, Haikou  570311, Hainan Province, China
  • Online:2010-07-02 Published:2010-07-02
  • About author:Wang Zhi-ming, Associate chief physician, Department of Hematology, Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University, Haikou People’s Hospital, Haikou 570208, Hainan Province, China wzm8282@126.com
  • Supported by:

    the Natural Science Foundation of Hainan Province in 2008, No. 30869*

PDF

396

Abstract:

BACKGROUND: Haploidentical hematopoietic stem cell transplantation is confronted with many problems such as difficulty to implant, slow reconstitution, severe graft versus host disease, delayed immunologic reconstitution, and high incidence rate of lethal infection. To overcome these problems can widely use the transplantation of haploidentical hematopoietic stem cells.
OBJECTIVE: To study the effect of haploidentical hematopoietic stem cell transplantation in treatment of hematologic malignancies.
METHODS: We used cytosine arabinoside, busulphan, cyclophosphamide，the anti-thymocyte globulin and methyl-n-(2-chloroethlyl)-n-cyclohexyl-n-nitrosourea as preconditioning of patients, used cyclosporine A, mycophenolate mofetil, the anti-thymocyte globulin, interleukin-11 and methotrexate as prophylaxis of acute graft versus host diseases to treat 6 cases of hematologic malignancies.
RESULTS AND CONCLUSION: All patients achieved complete engraftment. The median times of neutrophil recovery > 1.0×109/L were 15.8 (+12-+20) days after transplantation. The incidence of grade Ⅲ-Ⅳgraft-versus-host disease was 16.7%. All patients survived disease-free with a median follow-up of 34.7(13-63) months. Results have indicated that haploidentical hematopoietic stem cell transplantation is a safe and effective treatment for hematologic malignancies, with cytosine arabinoside, busulphan, cyclophosphamide, the anti-thymocyte globulin, methyl-n-(2-chloroethlyl)-n-cyclohexyl-n-nitrosourea as preconditioning, with cyclosporine A, mycophenolate mofetil, the anti-thymocyte globulin, interleukin-11 and methotrexate as prophylaxis of acute graft versus host diseases.

CLC Number: